Aktienanalyse zu Neurogene Inc (NGNE)NGNENeurogene Inc

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Neurogene Inc is a good buy right now due to its current price of $23.25, which is significantly lower than the analyst price target of $60 from JPMorgan, suggesting a potential upside of 132%. Additionally, the stock has a low RSI of 36.279, indicating it may be oversold, making it an attractive entry point for long-term investors. However, the company has reported substantial net losses, with a net income of -34,488,000 USD in Q2 2026, which remains a key risk.